A method of inhibiting an overactive fibroblast growth factor receptor 3 (FGFR3) in a cell by contacting the cell with a composition that contains an effective amount of Pheophorbide a, Pyropheophorbide a, or an active derivative thereof. Also disclosed is a method for treating a disorder associated with an overactive FGFR3 with a composition containing an effective amount of Pheophorbide a, Pyropheophorbide a, or an active derivative thereof. Further, a composition for treating a disorder associated with an overactive FGFR3 is described. The composition contains an ethanol extract of Amaranthus viridis.

A pharmaceutical composition containing dry powder of pine (Pinus) needles and dry peels and pits of grapes extract and pharmaceutically acceptable additive, dry extracts of ginger (Zingiber officinale), turmeric (Curcuma longa), white peony (Paeonia), Rhodiola Rosea (Rhodiola Rosea), apricot (Prunus) seed, oyster mushroom (Pleurotus ostreatus), green tea (Camellia sinensis), Ginkgo Biloba (Ginkgo biloba), white pepper, pomegranate (Punica granatum) pulp, medlar (Mespilus germanica), dry powder of pomegranate (Punica granatum) juice and folic acid, in the following ratio of the components in weight % (w %):

TABLE-US-00001 dry powder of pine needles and dry peels and pits of grapes extract and pharmaceutically acceptable additive 6-24 dry extract of ginger 6-25 dry extract of turmeric 5-24 dry extract of white peony 2-20 dry extract of Rhodiola Rosea 2-20 dry extract of apricot seed 5-20 dry extract of oyster mushroom 10-34 dry extract of green tea 12-35 dry extract of Ginkgo Biloba 2-25 dry extract of white pepper 1-15 dry extract of pomegranate pulp 2-20 extract of medlar 2-20 dry powder of pomegranate juice 2-25 folic acid 3-30

A pharmaceutical composition containing dry powder of pine (Pinus) needles and dry peels and pits of grapes extract and pharmaceutically acceptable additive, dry extracts of ginger (Zingiber officinale), turmeric (Curcuma longa), white peony (Paeonia), Rhodiola Rosea (Rhodiola Rosea), apricot (Prunus) seed, oyster mushroom (Pleurotus ostreatus), green tea (Camellia sinensis), Ginkgo Biloba (Ginkgo biloba), white pepper, pomegranate (Punica granatum) pulp, medlar (Mespilus germanica), dry powder of pomegranate (Punica granatum) juice and folic acid, in the following ratio of the components in weight % (w %):

TABLE-US-00001 dry powder of pine needles and dry peels and pits of grapes extract and pharmaceutically acceptable additive 6-24 dry extract of ginger 6-25 dry extract of turmeric 5-24 dry extract of white peony 2-20 dry extract of Rhodiola Rosea 2-20 dry extract of apricot seed 5-20 dry extract of oyster mushroom 10-34 dry extract of green tea 12-35 dry extract of Ginkgo Biloba 2-25 dry extract of white pepper 1-15 dry extract of pomegranate pulp 2-20 extract of medlar 2-20 dry powder of pomegranate juice 2-25 folic acid 3-30

The present invention relates to a pharmaceutical composition capable of inhibiting replication of coronavirus in a subject upon administrating the composition in an effective amount to the subject, the composition comprising an extract acquired from a plant part of Boesenbergia sp. having Panduratin A and Pinostrobin in a molar ratio of 1:4 to 1:10. The composition may further comprise or incorporated with or being used along with an antiviral agent to achieve a synergistic effect against coronavirus.

The present invention relates to a pharmaceutical composition capable of inhibiting replication of coronavirus in a subject upon administrating the composition in an effective amount to the subject, the composition comprising an extract acquired from a plant part of Boesenbergia sp. having Panduratin A and Pinostrobin in a molar ratio of 1:4 to 1:10. The composition may further comprise or incorporated with or being used along with an antiviral agent to achieve a synergistic effect against coronavirus.

A method for determining a numerical score representative of a patient's health, is characterized by the following steps. At an initial calibration step, a database is established from a series of indicators relating to the state of health of the patient, each indicator being assigned a numerical value, and afterwards a statistical analysis of this database is performed so as to establish for each of said indicators a score depending on a measured value of the indicators of the state of health with respect to reference values, and to establish at least four groups constituted by said indicators, each of said groups representing information corresponding respectively to oxidative stress, hereinafter Group 1; to functions of the digestive brain, hereinafter Group 2; to functions of the reptilian brain, hereinafter Group 3; and to physical abilities of the patient coupled to his information on his general state of health, hereinafter Group 4. Furthermore, a value is assigned to each group, then a health score S specific to the patient is calculated using the formula:

S=(Value Group 1+(2* Value Group 2)+(2* Value Group 3)+(3* Value Group 4))/(2* Number of groups)

A method for determining a numerical score representative of a patient's health, is characterized by the following steps. At an initial calibration step, a database is established from a series of indicators relating to the state of health of the patient, each indicator being assigned a numerical value, and afterwards a statistical analysis of this database is performed so as to establish for each of said indicators a score depending on a measured value of the indicators of the state of health with respect to reference values, and to establish at least four groups constituted by said indicators, each of said groups representing information corresponding respectively to oxidative stress, hereinafter Group 1; to functions of the digestive brain, hereinafter Group 2; to functions of the reptilian brain, hereinafter Group 3; and to physical abilities of the patient coupled to his information on his general state of health, hereinafter Group 4. Furthermore, a value is assigned to each group, then a health score S specific to the patient is calculated using the formula:

S=(Value Group 1+(2* Value Group 2)+(2* Value Group 3)+(3* Value Group 4))/(2* Number of groups)

Disclosed is a combination of lipophilic extracts of Zingiber officinale and Echinacea angustifolia for the treatment of itching, peripheral pain, superficial and deep inflammatory and painful states, pain associated with muscle spasms, herpes pain, and radiodermatitis caused by oncological radiotherapy, with or without fungal or bacterial infections.

A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.